Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders

[1]  Tehseen Noorani.  Erratum: Making psychedelics into medicines: The politics and paradoxes of medicalization , 2019, Journal of Psychedelic Studies.

[2]  T. Lea,et al.  Psychedelic Microdosing: A Subreddit Analysis , 2020, Journal of psychoactive drugs.

[3]  K. Kuypers,et al.  Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers , 2019, Front. Psychiatry.

[4]  Heith Copes,et al.  Narrative identity, rationality, and microdosing classic psychedelics. , 2019, The International journal on drug policy.

[5]  L. Pani,et al.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research , 2019, Journal of psychopharmacology.

[6]  Dan T. Rosenbaum,et al.  Psychedelic microdosing benefits and challenges: an empirical codebook , 2019, Harm Reduction Journal.

[7]  D. Nutt,et al.  First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants , 2019, BMJ Case Reports.

[8]  H. de Wit,et al.  Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers , 2019, Biological Psychiatry.

[9]  J. Fadiman,et al.  Descriptive assemblage of psychedelic microdosing: Netnographic study of Youtube™ videos and on-going research projects , 2019, Performance Enhancement & Health.

[10]  K. Kuypers,et al.  Motives and Side-Effects of Microdosing With Psychedelics Among Users , 2019, The international journal of neuropsychopharmacology.

[11]  Z. Walsh,et al.  MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials , 2019, Psychopharmacology.

[12]  E. Argento,et al.  The tripping point: The potential role of psychedelic-assisted therapy in the response to the opioid crisis. , 2019, The International journal on drug policy.

[13]  J. Fadiman,et al.  Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration , 2019, Journal of psychoactive drugs.

[14]  R. Stevenson,et al.  A systematic study of microdosing psychedelics , 2018, PloS one.

[15]  J. Read,et al.  Staying on, and coming off, antidepressants: The experiences of 752 UK adults. , 2019, Addictive behaviors.

[16]  H. Wit,et al.  Acute subjective and behavioral effects of microdoses of LSD in healthy human volunteers , 2019 .

[17]  D. Terhune,et al.  The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial , 2018, Psychopharmacology.

[18]  Dan T. Rosenbaum,et al.  Microdosing psychedelics: personality, mental health, and creativity differences in microdosers , 2018, Psychopharmacology.

[19]  Phil Hutchinson,et al.  The Meaning Response, "Placebo," and Methods , 2018, Perspectives in biology and medicine.

[20]  D. E. Olson.  Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics , 2018, Journal of experimental neuroscience.

[21]  B. Hommel,et al.  Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting , 2018, bioRxiv.

[22]  K. Kuypers,et al.  Mental health of a self-selected sample of psychedelic users and self-medication practices with psychedelics , 2018, Journal of Psychedelic Studies.

[23]  J. Ioannidis,et al.  Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.

[24]  T. Majić,et al.  Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[25]  P. Johnstad.  Powerful substances in tiny amounts , 2018, Nordisk alkohol- & narkotikatidskrift : NAT.

[26]  J. Moncrieff.  Against the stream: Antidepressants are not antidepressants – an alternative approach to drug action and implications for the use of antidepressants , 2018, BJPsych Bulletin.

[27]  D. Araujo,et al.  Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial , 2018, Psychological Medicine.

[28]  B. Sessa.  The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant , 2018, Psychopharmacology.

[29]  D. Nutt,et al.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up , 2017, Psychopharmacology.

[30]  Matthew W. Johnson,et al.  Long-term follow-up of psilocybin-facilitated smoking cessation , 2017, The American journal of drug and alcohol abuse.

[31]  H. Sackeim,et al.  Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression: When Enough Is Enough. , 2017, JAMA psychiatry.

[32]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[33]  B. Schmidt,et al.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial , 2016, Journal of psychopharmacology.

[34]  David E. Nichols,et al.  Psychedelics , 2016, Pharmacological Reviews.

[35]  L. Degenhardt,et al.  Sexual identity and prevalence of alcohol and other drug use among Australians in the general population. , 2016, The International journal on drug policy.

[36]  Jeesun Jung,et al.  Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. , 2016, JAMA psychiatry.

[37]  Hana Simonová,et al.  Ayahuasca Tourism: Participants in Shamanic Rituals and their Personality Styles, Motivation, Benefits and Risks , 2015, Journal of psychoactive drugs.

[38]  D. Nutt,et al.  Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse , 2015, Pharmacological Reviews.

[39]  B. Grant,et al.  Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. , 2015, JAMA psychiatry.

[40]  Guido Biele,et al.  A Meta-Analysis of Decision-Making and Attention in Adults With ADHD , 2015, Journal of attention disorders.

[41]  S. Seedat,et al.  Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. , 2015, The British journal of psychiatry : the journal of mental science.

[42]  R. Strassman,et al.  Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.

[43]  J. Strang,et al.  Solving the problem of non-attendance in substance abuse services. , 2014, Drug and alcohol review.

[44]  Matthew W. Johnson,et al.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.

[45]  T. Passie,et al.  Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.

[46]  H. Whiteford,et al.  Estimating treatment rates for mental disorders in Australia. , 2014, Australian health review : a publication of the Australian Hospital Association.

[47]  T. Vos,et al.  Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet.

[48]  T. S. Krebs,et al.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials , 2012, Journal of psychopharmacology.

[49]  J. Fadiman.  The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys , 2011 .

[50]  Klaus P. Ebmeier,et al.  A meta-analysis of depression severity and cognitive function. , 2009, Journal of affective disorders.

[51]  J. Suvisaari,et al.  A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. , 2008, Journal of affective disorders.

[52]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[53]  B. Löwe,et al.  A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.

[54]  B. Kupelnick,et al.  Patient adherence in the treatment of depression , 2002, British Journal of Psychiatry.

[55]  A. Antonovsky.  The structure and properties of the sense of coherence scale. , 1993, Social science & medicine.